Log in | Register

Optimization of meropenem dosage in the critically ill population based on renal function

Jared L. Crandon| Robert E. Ariano| Sheryl A. Zelenitsky| Anthony M. Nicasio| Joseph L. Kuti| David P. Nicolau
Original
Volume 37, Issue 4 / April , 2011

Pages 632 - 638

Abstract

Purpose

To develop a meropenem population pharmacokinetic model in critically ill patients with particular focus on optimizing dosing regimens based on renal function.

Methods

Population pharmacokinetic analysis was performed with creatinine clearance (CrCl) and adjusted body weight to predict parameter estimates. Initial modeling was performed on 21 patients (55 samples). Validation was conducted with 12 samples from 5 randomly selected patients excluded from the original model. A 5,000-patient Monte Carlo simulation was used to ascertain optimal dosing regimens for three CrCl ranges.

Results

Mean ± SD age, APACHE, and CrCl were 59.2 ± 16.8 years, 13.6 ± 7, and 78.3 ± 33.7 mL/min. Meropenem doses ranged from 0.5 g every 8 h (q8h)–2 g q8h as 0.5–3 h infusions. Median estimates for volume of the central compartment, K12, and K21 were 0.24 L/kg, 0.49 h−1, and 0.65 h−1, respectively. K10 was described by the equation: K10 = 0.3922 + 0.0025 × CrCl. Model bias and precision were −1.9 and 8.1 mg/L. R2, bias, and precision for the validation were 93%, 1.1, and 2.6 mg/L. At minimum inhibitory concentrations (MICs) up to 8 mg/L, the probability of achieving 40% fT > MIC was 96, 90, and 61% for 3 h infusions of 2 g q8h, 1 g q8h, and 1 g q12h in patients with CrCl ≥50, 30–49, and 10–29, respectively. Target attainment was 75, 65, and 44% for these same dosing regimens as 0.5 h infusions.

Conclusions

This pharmacokinetic model is capable of accurately estimating meropenem concentrations in critically ill patients over a range of CrCl values. Compared with 0.5 h infusions, regimens employing prolonged infusions improved target attainment across all CrCl ranges.

Keywords

References

  1. Merrem (2007) (Meropenem) package insert. AstraZeneca, Wilmington
  2. Li C, Kuti JL, Nightingale CH, Nicolau DP (2006) Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 46:1171–1178
    • View reference on publisher's website
    • View reference on PubMed
  3. Clinical Laboratory Standard Institute (2008) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 8th ed. CLSI Publication M07-A8, Wayne
  4. DeRyke CA, Kuti JL, Nicolau DP (2007) Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 58:337–344
    • View reference on publisher's website
    • View reference on PubMed
  5. Ikawa K, Morikawa N, Ikeda K, Ohge H, Sueda T (2008) Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid. J Infect Chemother 14:330–332
    • View reference on publisher's website
    • View reference on PubMed
  6. Drusano GL (2004) Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2:289–300
    • View reference on publisher's website
    • View reference on PubMed
  7. Turnidge JD (1998) The pharmacodynamics of beta-lactams. Clin Infect Dis 27:10–22
    • View reference on publisher's website
    • View reference on PubMed
  8. Eggimann P, Pittet D (2001) Infection control in the ICU. Chest 120:2059–2093
    • View reference on publisher's website
    • View reference on PubMed
  9. Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840–851 quiz 859
    • View reference on publisher's website
    • View reference on PubMed
  10. Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA (2001) Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 45:13–22
    • View reference on publisher's website
    • View reference on PubMed
  11. Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL (2009) Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 25:69–77
    • View reference on publisher's website
    • View reference on PubMed
  12. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J (2009) Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64:142–150
    • View reference on publisher's website
    • View reference on PubMed
  13. Elkhaili H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl F (1996) High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B Biomed Appl 686:19–26
    • View reference on publisher's website
    • View reference on PubMed
  14. Leary RJ, Schumitzky A, Van Guilder M (2001) An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. In: Proceedings, fouteenth IEEE symposium on computer-based medical systems. IEEE Computer Society, Bethesda, pp 389–394
  15. Crandon JL, Kuti JL, Jones RN, Nicolau DP (2009) Comparison of 2002–2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Ann Pharmacother 43:220–227
    • View reference on PubMed
  16. Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA (2002) Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 19:105–110
    • View reference on publisher's website
    • View reference on PubMed
  17. Krueger WA, Bulitta J, Kinzig-Schippers M, Landersdorfer C, Holzgrabe U, Naber KG, Drusano GL, Sorgel F (2005) Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 49:1881–1889
    • View reference on publisher's website
    • View reference on PubMed
  18. Lee DG, Choi SM, Shin WS, Lah HO, Yim DS (2006) Population pharmacokinetics of meropenem in febrile neutropenic patients in Korea. Int J Antimicrob Agents 28:333–339
    • View reference on publisher's website
    • View reference on PubMed
  19. Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR (2005) Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 44:539–549
    • View reference on publisher's website
    • View reference on PubMed
  20. Thalhammer F, Traunmuller F, El Menyawi I, Frass M, Hollenstein UM, Locker GJ, Stoiser B, Staudinger T, Thalhammer-Scherrer R, Burgmann H (1999) Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 43:523–527
    • View reference on publisher's website
    • View reference on PubMed
  21. Couchoud C, Pozet N, Labeeuw M, Pouteil-Noble C (1999) Screening early renal failure: cut-off values for serum creatinine as an indicator of renal impairment. Kidney Int 55:1878–1884
    • View reference on publisher's website
    • View reference on PubMed
  22. Lipman J, Wallis SC, Boots RJ (2003) Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 97:1149–1154 (table of contents)
    • View reference on publisher's website
    • View reference on PubMed
  23. Chow KM, Hui AC, Szeto CC (2005) Neurotoxicity induced by beta-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 24:649–653
    • View reference on publisher's website
    • View reference on PubMed
  24. Bulik CC, Quintiliani Jr R, Samuel Pope J, Kuti JL, Nicolau DP (2009) Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis—a review of 3 cases. Resp Med CME E pub
  25. Li C, Du X, Kuti JL, Nicolau DP (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725–1730
    • View reference on publisher's website
    • View reference on PubMed

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement